a patient with vasculitis shall be said to have giant cell temporal arteritis if at least three of these five criteria are present. Giant cell arteritis (GCA) is a medical emergency. The concept ...

Giant cell arteritis, also called temporal arteritis, is a disease that causes your arteries -- blood vessels that carry oxygen from your heart to the rest of your body -- to become inflamed.

Temporal arteritis is also known as cranial arteritis or giant cell arteritis ... causes, diagnosis criteria, and possible complications. These symptoms can also occur due to other conditions ...

Findings showed 46.4% of patients treated with upadacitinib 15mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

In this Healio Video Perspective, Andrew G. Lee, MD, discusses whether temporal artery ultrasound can be used in place of ...

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

for the treatment of adults with giant cell arteritis (GCA). 1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...

The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA) 1 The primary ...